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Background: To quantitatively evaluate the safety and related-toxicities of intensity modulated radiotherapy (IMRT)
dose–volume histograms (DVHs), as compared to the conventional three-dimensional conformal radiotherapy
(3D-CRT), in gynecologic malignancy patients by systematic review of the related publications and meta-analysis.
Methods: Relevant articles were retrieved from the PubMed, Embase, and Cochrane Library databases up to
August 2011. Two independent reviewers assessed the included studies and extracted data. Pooled average
percent irradiated volumes of adjacent non-cancerous tissues were calculated and compared between IMRT and
3D-CRT for a range of common radiation doses (5-45Gy).
Results: In total, 13 articles comprised of 222 IMRT-treated and 233 3D-CRT-treated patients were included. For
rectum receiving doses ≥30 Gy, the IMRT pooled average irradiated volumes were less than those from 3D-CRT
by 26.40% (30 Gy, p = 0.004), 27.00% (35 Gy, p = 0.040), 37.30% (40 Gy, p = 0.006), and 39.50% (45 Gy, p = 0.002).
Reduction in irradiated small bowel was also observed for IMRT-delivered 40 Gy and 45 Gy (by 17.80% (p = 0.043)
and 17.30% (p = 0.012), respectively), as compared with 3D-CRT. However, there were no significant differences in
the IMRT and 3D-CRT pooled average percent volumes of irradiated small bowel or rectum from lower doses, or in
the bladder or bone marrow from any of the doses. IMRT-treated patients did not experience more severe acute
or chronic toxicities than 3D-CRT-treated patients.
Conclusions: IMRT-delivered high radiation dose produced significantly less average percent volumes of irradiated
rectum and small bowel than 3D-CRT, but did not differentially affect the average percent volumes in the bladder
and bone marrow.
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Radiotherapy (RT) plays an important role in the adju-
vant treatment of gynecologic malignancies, particularly
in cervical and endometrial cancer. While RT has
greatly improved local regional control of primary
tumors [1-3], it has come at the cost of significant
toxic effects to adjacent non-cancerous tissues [4,5]. In
the late 1990s, the technique of three-dimensional con-
formal radiation therapy (3D-CRT) emerged as a pre-
ferred treatment for gynecologic malignancies, since it
gave better target coverage and significantly reduced
the radiation exposure to the bladder [6]. However, this
technique did not appreciably reduce the amount of ra-
diation exposure to the intestine or rectum [7]. More
recent advances in computer technology have led to
improvements on the 3D-CRT technique; one, in par-
ticular, being the development of intensity modulated
radiation therapy (IMRT) [8-12]. In contrast to 3D-
CRT, which uses uniform fields, IMRT generates non-
uniform fields to achieve better planning target volume
coverage, while decreasing unnecessary radiation expos-
ure to normal organs [9,13,14]. Therefore, IMRT has
become a common strategy for whole pelvic radiother-
apy (WPRT), and has been shown to offer more accur-
ate dose distributions and tighter dose gradients to
targets and to reduce toxic risk and undesirable side
effects to the rectum, bladder, small bowel, and pelvic
bones [15-18].
IMRT has also proven an efficacious and safe method
of treating head, neck, lung, central nervous system,
breast, and prostate cancers [19-23]. While the method
has been applied to cervical and endometrial cancers as
well [17,18,24-31], the reported findings on its utility
and safety in these patients have been controversial.
Thus, in the late 2000s, the National Comprehensive
Cancer Network (NCCN) reported that IMRT treat-
ment for gynecologic malignancy was not sufficiently
well-established for general recommendation [32]. The
main problems cited were the facts that the target site
and parameters of posture immobilization remained to
be precisely defined, and that the repeatability of an
IMRT model remained to be demonstrated [32].
Nonetheless, the previous successes of IMRT in other
cancer patients have promoted significant research
interest to evaluate its promise for treating gynecologic
malignancy patients [33]. In addition, the proven bene-
fits of IMRT over the 3D-CRT technique have led to
several studies to determine whether IMRT is superior
to 3D-CRT for the clinical treatment of gynecologic
malignancies. With the aim of resolving the inconsist-
encies that have arisen from these studies, we con-
ducted a systematic review and meta-analysis of IMRT
and 3D-CRT use in gynecologic malignancy patients. In
addition to quantitatively evaluating the safety of IMRTin these patients, we also performed a comparative ana-
lysis of the dose–volume histograms (DVHs) generated
for both IMRT and 3D-CRT. Finally, the acute and




The PubMed, Embase, and Cochrane Library databases
were searched for relevant publications by using the fol-
lowing keywords: “radiotherapy, intensity modulated”,
“IMRT”, “cervical cancer”, “cervix cancer”, “cervical car-
cinoma”, “cervix carcinoma”, “endometrial cancer”,
“endometrial carcinoma”, and “gynecologic malignan-
cies”. The upper publication date was August 2011 and
no lower date was set. These terms were then combined
with the search terms for the following study designs:
“practice guideline”, “systematic review”, “meta-analysis”,
and “review”. In addition, the reference lists of all pertin-
ent articles found in PubMed were manually searched.
The Physician Data Query (PDQ) clinical trials data-
base and the proceedings of the 1980–2010 annual
meetings of the American Society of Clinical Oncology
(ASCO) and the American Society of Radiation Therap-
ist (ASTRO) were also searched for reports of new or
on-going trials.
Criteria for study inclusion and exclusion
A study was selected for inclusion if it provided informa-
tion on DVHs of different irradiated organs that had
been treated with IMRT or 3D-CRT. Those studies were
then selected for the following criteria: 1) prescription
dose of Gy or 50.4 Gy, for either IMRT or 3D-CRT, with
all patients having received radiation doses of 1.8 Gy/
day; 2) irradiated normal organs at risk being small
bowel, bladder, rectum, and bone marrow; 3) data from
the DVHs in irradiated organs at risk being relative
number and not the actual measured value; and 4) stud-
ies being independent and not replicates of a single
population. If studies were found to overlap, the largest
dataset was selected for inclusion. A flowchart of the
strategy used for this systematic review of the literature
is presented in Figure 1.
Data extraction
The data from each included study were extracted by
two reviewers (Lin Zhu and Baojuan Yang), who worked
independently and used a standardized form for data
collection. Any subsequent discrepancies were discussed
and revised until a consensus was achieved. Information
extracted from each article included the first author,
country of origin, number of patients, normal organs
irradiated, prescribed dose of IMRT and 3D-CRT, and
average percent irradiated volumes of the organs at risk
Figure 1 Flow chart of identification and selection of papers for study.
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the interval of each level was 5 Gy) in DVHs.
In regards to the DVHs information, if the authors
did not list the average percent irradiated volumes of
OARs, we measured it based on the figures in the
article. If the prescribed dose in the study was 50.4 Gy
(indicating patients had received an additional three
days of 1.8 Gy/day), we only extracted the data for
radiated doses <45 Gy.Statistical analysis
To assess heterogeneity of the studies, a fixed effect
model based on the Mantel-Haenszel method was used
to calculate the pooled average percent irradiated
volumes, if I2 was less than 50%; otherwise, a random ef-
fect model was used. The pooled average percent irra-
diated volumes for IMRT and 3D-CRT treatment plans
were compared at each radiation dose in OARs (includ-
ing small bowel, bladder, rectum, and bone marrow).
Differences were considered to be statistically significant
if the p-value was less than 0.05. Publication bias was
evaluated by funnel plot, followed by a quantitative ana-
lysis using a linear regression approach and rank correl-
ation method [34,35]. For this study, all data analyses
were performed by the Comprehensive Meta-analysis
software (version 2; Biostat, Inc., USA), and the statistical
analyses were carried out with SAS software (version 9.1;
SAS Institute, USA).Results
Characteristics of the included studies
In total, 13 articles, which compared the extents of
DVHs in IMRT and 3D-CRT for endometrial and cer-
vical cancer patients, were included. Ten of these
reported on the irradiated volumes of small bowel, nine
on rectum, eight on bladder, and six on bone marrow.
The 13 articles comprised a total of 222 patients treated
with IMRT and 233 patients treated with 3D-CRT. The
prescribed dose was either 45 Gy or 50.4 Gy, and all
patients received treatment at 1.8 Gy/y. The characteris-
tics of the included articles are summarized in Table 1.
Pooled average percent irradiated volumes of IMRT and
3D-CRT
The pooled average percent irradiated volumes of IMRT
and 3D-CRT were calculated for different OARs and
compared for each irradiated level (Table 2). For rectums
treated with <30 Gy, the pooled average irradiated
volumes were not statistically different between IMRT
and 3D-CRT. However, rectums that received ≥30 Gy
doses had significantly lower pooled average irradiated
volumes for IMRT (30 Gy, 68.00 (95% CI: 56.60-77.50);
35 Gy, 61.80 (95% CI: 48.80-73.30); 40 Gy, 48.10 (95%
CI: 26.90-70.10); and 45 Gy, 31.30 (95% CI: 13.20-
57.70)) than for 3D-CRT (94.40 (95% CI: 86.20-96.80);
88.80 (95% CI: 74.70-95.50); 85.40 (95% CI: 74.40-92.20);
and 70.80 (95% CI: 59.60-80.00)). Thus, the pooled aver-
age irradiated volumes of IMRT were lower than that of





Sample size Organs at risk Level of the dose, Gy
IMRT* 3D-CRT+
Heron DE [26] USA 45 10 10 Rectum, Small bowel, Bladder 10, 20, 30, 40, 45
Chen MF [36] Taiwan 50.4 33 35 Rectum, Small bowel, Bladder, Bone marrow 5, 10, 15, 20, 25, 30, 35, 40, 45
Mell LK [30] USA 45 7 7 Rectum, Small bowel, Bladder, Bone marrow 5, 10, 20, 30, 40, 45
Igdem S [31] Turkey 45 or 50.4 10 10 Rectum, Small bowel, Bladder, Bone marrow 5, 10, 15, 20, 25, 30, 40, 45
Roeske JC [37] USA 45 10 10 Rectum, Small bowel, Bladder 5, 10, 15, 20, 25, 30, 35, 40, 45
Portelance L [17] USA 45 10 10 Rectum, Small bowel, Bladder 45
Lujan AE [38] USA 45 10 10 Bone marrow 5, 10, 15, 20, 25, 30, 35, 40, 45
Brixey CJ [39] USA 45 36 88 Iliac crest, Lumbar spine, Sacrum 5, 10, 15, 20, 25, 30, 35, 40, 45
Ahmed RS [27] USA 45 5 5 Bone marrow 5, 10, 15, 20, 25, 30, 35, 40, 45
Mell LK [37] USA 45 37 0 Bone marrow 10, 20, 30, 40
Mundt AJ [38] USA 45 36 30 Small bowel 5, 10, 15, 20, 25, 30, 35, 40, 45
Salama JK [40] USA 45 13 13 Rectum, Small bowel 5, 10, 15, 20, 25, 30, 35, 40, 45
Georg D [41] Austria 50.4 5 5 Rectum, Small bowel, Bladder 5, 10, 15, 20, 25, 30, 35, 40, 45
* intensity modulated radiotherapy; + three-dimensional conformal radiotherapy.
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37.30% (p = 0.006), and 39.50% (p = 0.002), respectively.
Furthermore, a statistically significant dose–response re-
lationship was observed between increasing Gy of irradi-
ation doses and decreasing pooled average percent
volumes (P = 0.003).
In small bowel, the pooled average percent volumes
were significantly lower (by 17.80%) for IMRT than for
3D-CRT at a radiation dose of 40 Gy (IMRT: 24.70%
(95% CI: 17.30-34.10) and 3D-CRT: 42.50% (95% CI:
24.00-63.40); p = 0.043). Similarly, at a dose of 45 Gy, the
pooled average percent volumes were 17.30% lower in
IMRT (IMRT: 18.60% (95% CI: 12.60-26.70) and 3D-
CRT: 35.90% (95% CI: 21.90-52.80); p = 0.012). At low
doses (<20 Gy), the pooled average percent volumes of
small bowel irradiated with IMRT were similar to those
for patients who received 3D-CRT treatment (p > 0.05).
Likewise, the doses between 25 Gy and 35 Gy did not
produce significantly different effects (p > 0.05), but ir-
radiation with IMRT did yield > 10% less percent pooled
average percent volumes than 3D-CRT.
The results of bladder and bone marrow from our
meta-analysis revealed that the pooled average irra-
diated volumes in IMRT were lower than those in 3D-
CRT. Although the differences were more obvious for
the higher doses of irradiation, none reached statistical
significance (Table 2).
Publication bias
The graphical funnel plots of pooled average percentage
volumes of small bowel irradiated at 45 Gy and rectum
irradiated at 30 Gy by IMRT and 3D-CRT are shown in
Figure 2. Although the dots were not entirely localized
to the bottom of the inverted funnel plots, they weredistributed symmetrically around the central axis. Using
the Begg’s rank correlation method and Egger’s linear re-
gression approach, we identified publication bias for the
40 Gy and 45 Gy radiation dose of the rectum with 3D-
CRT and for the 10 Gy, 25 Gy, and 40 Gy radiation
doses of the rectum with IMRT. Publication bias was
also found in several radiation dose levels of small bowel
with both IMRT and 3D-CRT, with the exceptions of 20
Gy, 30 Gy, and 35 Gy with IMRT and 5 Gy, 25 Gy, and
30 Gy with 3D-CRT. The results for the bladder and
bone marrow very nearly indicated publication bias for
all radiation doses, except for 25 Gy for the bladder and
15 Gy for bone marrow. The detailed results are pre-
sented in Table 2.
Acute and chronic toxicities
The acute and chronic toxicity effects of IMRT and 3D-
CRT were evaluated by investigating the reported side
effects of gastrointestinal (GI), genitourinary (GU), and
hematologic toxicity for each. Five studies that reported
on the toxic effects of IMRT and 3D-CRT were identi-
fied, including four on acute toxicity [25,36,42,43] and
three on chronic toxicity [36,39,43]. The acute (Table 3)
and chronic (Table 4) toxicities reported in recent series
of adjuvant IMRT for gynecologic malignancies were
graded using the Radiation Therapy Oncology Group
scales. Specifically, the worst toxicity was noted and
graded according to the following 4-point scale: 0, none;
1, mild, no medications required; 2, moderate, medica-
tions required; and 3–4, severe, treatment breaks,
hospitalization required.
In the studies by Mundt et al. [25] and Chen et al.
[36], none of the reported toxicities of gynecologic
patients treated with either IMRT or 3D-CRT met the







Pooled volume irradiated, % (95% CI) Egger’s p-value Begg’s p-value Studies trimmed Adjusted volume irradiated, % p-value⋆
IMRT* 3D-CRT+ IMRT* 3D-CRT+ IMRT* 3D-CRT+ IMRT* 3D-CRT+ IMRT* 3D-CRT+
Rectum 10 7 93 93.10 96.80 0.015 0.211 1.000 0.881 4 N/A 87.70 N/A 0.308
(83.80-97.30) (90.00-99.00)
20 7 93 87.80 97.50 0.303 0.406 0.327 0.624 N/A N/A N/A N/A 0.077
(73.70-94.90) (90.50-99.40)
25 5 76 90.00 97.40 0.045 0.142 0.368 0.652 3 N/A 86.00 N/A 0.101
(79.90-95.30) (89.30-99.40)
30 7 93 68.00 94.40 0.108 0.437 0.086 0.807 N/A N/A N/A N/A 0.004
(56.60-77.50) (86.20-96.80)
35 4 66 61.80 88.80 0.100 0.071 0.071 0.051 2 N/A 55.00 N/A 0.040
(48.80-73.30) (74.70-95.50)
40 7 93 48.10 85.40 0.030 0.052 0.174 0.308 N/A 3 N/A 80.10 0.002
(26.90-70.10) (74.40-92.20)
45 8 111 31.30 70.80 0.462 0.001 0.368 0.024 N/A 3 N/A 62.10 0.006
(13.20-57.70) (59.60-80.00)
Small bowel 5 5 102 97.20 96.70 0.001 0.271 0.076 1.000 1 N/A 96.70 N/A 0.831
(90.90-99.20) (89.50-99.00)
10 8 129 88.60 90.00 0.004 0.020 0.226 0.009 4 3 82.50 86.20 0.795
(79.00-94.20) (81.30-95.00)
15 6 112 85.90 86.10 0.011 0.001 0.060 0.060 2 1 80.30 83.80 0.985
(74.40-92.70) (75.00-92.80)
20 8 129 72.30 78.20 0.637 0.001 0.711 0.009 N/A 3 N/A 71.80 0.319
(63.70-83.70) (66.90-86.50)
25 6 112 62.20 73.90 0.036 0.114 1.000 0.060 3 N/A 77.40 N/A 0.431
(44.00-77.50) (49.10-89.30)
30 8 129 43.70 54.80 0.133 0.062 0.216 0.108 N/A N/A N/A N/A 0.186
(35.00-52.80) (34.30-73.80)
35 5 102 36.60 50.60 0.076 0.002 0.050 0.027 N/A 0 N/A 60.80 0.137
(27.70-46.60) (27.50-73.40)
40 8 129 24.70 42.50 0.049 0.005 0.266 0.035 3 2 28.10 58.10 0.043
(17.30-34.10) (24.00-63.40)

















Table 2 Pooled-average volumes irradiated (%) of IMRT and 3D-CRT in different risk organs and the publication bias (Continued)
Bladder 10 6 80 95.50 96.00 0.334 0.001 0.851 0.133 N/A 2 N/A 96.60 0.871
(86.40-98.60) (88.40-98.70)
20 6 80 88.90 96.00 0.151 0.001 0.707 0.133 N/A 2 N/A 96.60 0.169
(73.20-95.90) (88.40-98.70)
25 4 63 90.90 96.60 0.015 0.089 0.497 2 N/A 86.00 N/A 0.258
(76.60-96.80) (87.30-99.10)
30 6 80 81.20 94.60 0.227 0.153 0.133 0.260 N/A N/A N/A N/A 0.079
(61.60-92.10) (83.80-98.40)
35 3 53 80.60 89.70 0.936 0.029 1.000 0.296 N/A 2 N/A 85.00 0.396
(57.70-92.70) (70.70-96.90)
40 6 80 53.60 76.70 0.260 0.176 0.133 0.133 N/A N/A N/A N/A 0.090
(33.30-72.80) (59.10-88.30)
45 7 98 50.10 79.30 0.059 0.005 0.071 0.133 N/A 2 N/A 64.70 0.062
(31.70-68.50) (54.10-92.60)
Bone marrow 5 5 91/143 95.20 97.90 0.833 0.112 1.000 0.807 N/A N/A N/A N/A 0.501
(86.10-98.40) (83.60-99.80)
10 6 101/153 87.30 95.50 0.138 0.276 0.230 0.133 N/A N/A N/A N/A 0.129
(73.20-93.60) (86.00-98.60)
15 5 94/146 74.10 90.80 0.005 0.039 0.624 0.086 3 1 68.30 90.50 0.191
(61.10-83.90) (80.60-95.90)
20 6 101/153 67.40 68.50 0.165 0.005 0.368 0.707 N/A 3 N/A 63.40 0.301
(47.50-82.50) (55.40-79.30)
25 4 61/113 62.30 83.40 0.319 0.097 1.000 0.089 N/A N/A N/A N/A 0.061
(45.20-76.80) (66.50-92.70)
30 5 68/120 47.10 59.40 0.170 0.004 0.060 0.027 N/A 1 N/A 61.20 0.261
(32.50-62.20) (44.00-73.50)
35 3 51/103 36.80 51.70 0.065 0.074 0.296 1.000 N/A N/A N/A N/A 0.307
(19.90-57.80) (32.60-70.40)
40 5 68/120 29.70 40.20 0.859 0.187 1.000 0.462 N/A N/A N/A N/A 0.327
(17.50-45.70) (26.50-55.70)
45 4 61/113 12.80 31.00 0.070 0.099 0.308 0.089 N/A N/A N/A N/A 0.068
(5.00-28.90) (18.00-47.90)
















Figure 2 Funnel plots for pooled average percent irradiated volume. A. Small bowel at 45Gy with IMRT. B. Small bowel at 45Gy with 3D-
CRT. C. Rectum at 30Gy with IMRT. D. Rectum at 30Gy with 3D-CRT.
Table 3 Acute toxicities of IMRT and 3D-CRT
Reference Grade Cases of GI++ Cases of GU# Cases of Hematology
IMRT* 3D-CRT+ IMRT* 3D-CRT+ IMRT* 3D-CRT+
Mundt et al. [25] 0 5 0 28 21 N/D N/D
1 11 3 8 7 N/D N/D
2 24 32 4 7 N/D N/D
3-4 0 0 0 0 N/D N/D
total 40 35 40 35 N/D N/D
Beriwal et al. [42] 0 9 N/D 12 N/D 6 N/D
1 4 N/D 16 N/D 7 N/D
2 22 N/D 7 N/D 13 N/D
3-4 1 N/D 1 N/D 10 N/D
total 36 N/D 36 N/D 36 N/D
Hasselle et al. [43] 0 28 N/D 68 N/D N/D N/D
1 31 N/D 27 N/D N/D N/D
2 50 N/D 16 N/D N/D N/D
3-4 2 N/D 0 N/D N/D N/D
total 111 N/D 111 N/D N/D N/D
Chen et al. [36] 0 21 7 23 14 14 16
1 4 8 6 12 8 5
2 8 20 4 9 9 11
3-4 0 0 0 0 2 3
total 33 35 33 35 33 35
* intensity modulated radiotherapy; + three-dimensional conformal radiotherapy; ++ gastrointestinal; # genitourinary.
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Table 4 Chronic toxicities of IMRT and 3D-CRT
Reference Grade Cases of GI++ Cases of GU#
IMRT* 3D-CRT+ IMRT* 3D-CRT+
Mundt et al. [39] 0 32 15 N/D N/D
1 3 9 N/D N/D
2 1 5 N/D N/D
3-4 0 1 N/D N/D
total 36 30 N/D N/D
Hasselle et al. [43] 0 81 N/D 91 N/D
1 15 N/D 13 N/D
2 11 N/D 2 N/D
3-4 4 N/D 5 N/D
total 111 N/D 111 N/D
Chen et al. [36] 0 31 23 30 27
1 2 4 2 5
2 0 6 0 2
3-4 0 2 1 1
total 33 35 33 35
* intensity modulated radiotherapy; + three-dimensional conformal
radiotherapy;
++ gastrointestinal; # genitourinary.
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treatment did result in fewer patients with moderate
toxicity and needing medications than did 3D-CRT. In
the studies by Beriwal et al. [42] and Hasselle et al. [43],
severe acute GI, GU, and hematologic toxicities were
found in patients who underwent IMRT treatment.
However, these studies only evaluated patients with
IMRT and did not consider 3D-CRT treatment.
For chronic toxicities, most of the patients receiving
IMRT had no or mild side effects of GI and GU. The in-
cidence of severe GI side effects with IMRT was 2.20%
(4/180), and with 3D-CRT, the rate reached up to 4.60%
(3/65). Although Hasselle et al. [43] concluded that
IMRT caused a severe GU side effect, they did not com-
pare it with the incidence in 3D-CRT treatment groups.
In the study by Chen et al. [36], one patient from each
treatment group (3D-CRT: 1/35; IMRT: 1/36) was
reported to have experienced such severe side effects
from the treatment that hospitalization was required and
treatment terminated.
Discussion
Because IMRT can deliver treatment to target organs
while reducing the volumes of proximal normal struc-
tures that are irradiated, it appears to offer several
advantages over conventional techniques for the treatment
of malignancies [14] . However, studies on the effects of
IMRT in reducing the irradiated volumes of the rectum,
small bowel, bladder, and bone marrow have reported in-
consistent findings [18,26,27,30,31,36-41,44,45]. Therefore,we carried out a systematic review to identify all the
relevant studies presenting data on DVHs of IMRT and
3D-CRT. Consequently, data from 13 studies were ana-
lyzed by calculating the pooled average percent irra-
diated volumes, and they were used in a comparative
analysis of the effects of IMRT and 3D-CRT in the rec-
tum, small bowel, bladder, and bone marrow at various
radiation doses.
The studies by Heron et al. [26], Igdem et al. [31], and
Roeske et al. [37] reported that IMRT at doses of 30 Gy,
40 Gy, and 45 Gy significantly reduced the irradiated vol-
ume of the rectum, as compared to 3D-CRT. Chen et al.
[36] reported that, when patients received 70% of the
prescribed dose with IMRT, the average percent volume
of irradiated rectum was significantly less (p < 0.05).
However, the study by Mell et al. [30] found no signifi-
cant reduction in average percent volumes irradiated by
IMRT at those same doses. Our meta-analysis indicated
that the pooled average percent volumes of irradiated
rectum (at doses of 30 Gy, 35 Gy, 40 Gy, and 4 5Gy) were
significantly lower in IMRT than in 3D-CRT. Moreover,
this reduction manifested a dose response relationship
with increasing radiation doses (P = 0.003). Since some
publication bias existed in our meta-analysis, we adjusted
the reduction of volumes irradiated by using the trim
and fill method, and we found that the differences
retained statistical significance. This result illustrated
that, the higher the radiation dose prescribed, the better
IMRT was at reducing the average percent irradiated
volumes for the rectum, as compared to 3D-CRT.
Some studies have reported that IMRT treatment of
gynecologic malignancies more effectively protects the
small bowel compared to the 3D-CRT technique, espe-
cially when radiation doses <20 Gy are used [31]. In the
studies by Heron et al. [26] and Roeske et al. [37], it was
found that IMRT-delivered doses of >30 Gy and >45 Gy,
respectively, produced remarkably less average irradiated
volumes of OARs (by more than 10-fold) than 3D-CRT.
Other studies also reported that >25 Gy doses delivered
by IMRT were more beneficial than those delivered by
3D-CRT [39,44] . Our meta-analysis results showed that
after weighing the sample sizes, IMRT at 40 Gy and 45
Gy significantly reduced the pooled average percent irra-
diated volumes of the small bowel by 17.80% (p = 0.043)
and 17.30% (p = 0.012), respectively. However, at 35 Gy
and below, no statistically significant reduction was
found between IMRT and 3D-CRT in the pooled average
percent of irradiated volumes. In this meta-analysis,
there was no publication bias detected for data related
to IMRT-delivered 20 Gy, 30 Gy, or 35 Gy or for 3D-
CRT-delivered 5 Gy, 20 Gy, or 25 Gy. Although publi-
cation bias was observed for data related to both
IMRT- and 3D-CRT-delivered 40 Gy and 45 Gy radi-
ation doses, the reduction of pooled average percent
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with the trim and fill method.
This meta-analysis found no statistically significant evi-
dence to support the theory that IMRT was an effective
approach to reduce the irradiated volumes of the bladder.
Considering the effects of IMRT and 3D-CRT on bone
marrow, Brixey et al. [40] showed that IMRT produced
no obvious reduction in the volumes of OARs irradiated
at the 10 Gy and 30 Gy doses, but reported a statistically
significant reduction for doses of 20 Gy, 40 Gy, and 45
Gy (p < 0.001). In the studies by Lujun et al. [38] and
Ahmed et al. [27], the average percent volumes of irra-
diated OARs were found to be reduced at several high
radiation levels delivered by IMRT. In contrast, Chen
et al. [36]demonstrated a significant reduction in the
volume of irradiated bone marrow when IMRT delivered
doses of 20 Gy and below. When these seemingly incon-
sistent results were combined in our meta-analysis,
IMRT was found to reduce the average percent volumes
of irradiated bone marrow at all radiation doses, but the
findings did not reach statistical significance (p > 0.05).
Publication bias was observed only for the IMRT-
delivered dose of 15 Gy and 3D-CRT-delivered doses of
15 Gy, 20 Gy, and 30 Gy. After adjusting the reduction
of irradiated volumes by using the trim and fill method,
there was still no statistically significant reduction found
between IMRT and 3D-CRT.
High heterogeneity was found for the data of bladder
and rectum irradiation from high radiation doses deliv-
ered by IMRT and for the data of small bowel and blad-
der irradiation from 40 Gy and 45 Gy doses delivered by
3D-CRT. Potential explanations exist to explain these
instances of heterogeneity. First, the OARs in the ab-
dominal cavity are not static and are in continual mo-
tion, and the volumes of irradiated organs are known to
be impacted by different postures. Second, the RT physi-
cians defined the extent of OARs that were reported in
each study, and they may not have abided by a unified
standard. Third, the data from each study was generated
independently and may have been influenced by the par-
ticular study design.
In our meta-analysis, we determined that toxicity
occurred with significantly lower frequency in the IMRT
treated patients than in the 3D-CRT patients [25,39,46].
In the studies by Mundt et al. [25] and Chen et al. [36],
adjuvant IMRT was reported to be well-tolerated with
low incidences of acute and chronic toxicity, as com-
pared with 3D-CRT. Although several patients in the
studies by Beriwal et al. [42] and Hasselle et al. [43] suf-
fered severe acute and chronic toxicities from IMRT, the
incidence of these side effects was not compared with
that of 3D-CRT. These two research studies prompted
us to theorize that the most significant factor correlated
to IMRT-induced toxicity in gynecologic patients is theorgan volume receiving 100% (45 Gy) of the prescription
dose [47]. Likewise, Rose et al. [48] provided evidence
that hematologic toxicity increased with increasing
volumes of irradiated pelvic bone marrow.
Finally, the collected IMRT dosimetric data from gyne-
cologic patients used in our meta-analysis suggested that
IMRT is safe for use as a treatment of gynecologic can-
cers. However, all of the research studies with which our
meta-analysis was carried out were observational. It is
generally believed that findings from observational stud-
ies are not as accurate as those from randomized con-
trolled trials, since they can easily overestimate the
magnitude of effects. Another limitation in our study
was the small sample size and uneven quality of the
samples. Thus, our conclusions need to be validated by
larger samples and more studies to confirm the benefits
of IMRT in patients with gynecologic malignancy and to
further study the different acute and chronic toxicities
produced by IMRT and 3D-CRT.
Conclusions
This study suggested that IMRT significantly reduced
the average percent irradiated volume of the rectum
resulting from >30 Gy doses and of the small bowel
from 45 Gy. Furthermore, in the bladder and bone mar-
row, the advantages of IMRT over 3D-CRT were not sig-
nificant for any of the radiation doses examined.
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